Catheter Precision (NYSE:VTAK) shares are down on Thursday as the company announced a strategic divestiture of its non-core assets.VTAK Sells Atherectomy Catheter Tech to Focus on ElectrophysiologyCatheter Precision on Thursday agreed to sell its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer.This decision aims to enhance capital efficiency and sharpen the company’s focus on its high-growth electrophysiology platform.The divestiture is expected to ...

Core Viewpoint - Catheter Precision, Inc. has announced a definitive agreement to divest its atherectomy catheter technologies, enhancing capital efficiency and focusing on its high-growth electrophysiology platform [1][2]. Strategic Rationale - The transaction is expected to accelerate execution across the electrophysiology product portfolio while maintaining exposure to the future commercial success of the divested technologies [4]. Transaction Highlights - The company will receive an upfront cash payment of $15 million upon closing [7]. - It will retain a 5% equity stake in the acquiring company, with anti-dilution protection for up to $5 million of additional equity capital invested [7]. - A ten-year royalty payments agreement will be established, starting with a 1.5% baseline that increases to 3% on quarterly net sales exceeding $5 million [7]. - The transaction is designed to create potential long-term equity upside participation and recurring revenue through performance-based royalties [7]. Company Overview - Catheter Precision is a U.S.-based medical device company focused on advancing the treatment of cardiac arrhythmias through innovative electrophysiology technologies developed in collaboration with leading physicians [5].

Strategic Partnership: Creatd expanded Fly Flyte’s investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB: CRTD) announced that Catheter Precision, Inc. (NYSE Amer ...

Core Insights - Catheter Precision, Inc. has made a strategic minority investment in Fly Flyte, Inc., a regional aviation operator, to gain immediate exposure to a revenue-generating, asset-backed business in the air mobility sector [1][10] Investment Overview - The investment allows Catheter Precision to acquire a 19.98% equity ownership in Flyte, providing access to one of the fastest-growing segments of private aviation [7] - Flyte operates under FAA certification and is currently generating revenue with its fleet of Cirrus Vision Jets, which are equipped with advanced safety features [2][8] Strategic Positioning - Flyte is positioned to benefit from the anticipated future commercialization of electric vertical takeoff and landing (eVTOL) aircraft, operating in the same corridors targeted for future electric aircraft integration [5][6] - The company leverages certified aircraft and established infrastructure to generate active revenue and customer engagement, which is crucial for long-term capital investment [6][9] Operational Efficiency - Flyte employs AI-enabled optimization across various operational aspects, including routing, pricing, and dispatch, contributing to a capital-efficient growth model [8] - The company maintains a disciplined approach to expansion, targeting scalable revenue growth while preserving capital efficiency [4][11] Long-Term Value Creation - The investment reflects a broader strategy of Catheter Precision to deploy capital into businesses with scalable infrastructure and clear paths to long-term value creation [10][16] - Flyte's model is designed for disciplined execution and measured growth, positioning it well for the evolving regional air mobility landscape [11]

Core Viewpoint - Catheter Precision, Inc. has terminated its at-the-market equity offering program and secured a strategic financing transaction with institutional investors for up to $36.5 million to support accelerated growth [1][3]. Group 1: Financial Position and Strategy - The termination of the ATM equity offering program is aimed at strengthening the company's balance sheet and aligning with long-term institutional capital for value creation [1][3]. - The strategic financing enhances institutional investor confidence in the company's strategy and eliminates legacy financing overhang [3][7]. - The company has converted short-term notes to long-term by extending maturities to two and three years, significantly strengthening its balance sheet and liquidity [7]. Group 2: Growth Initiatives - The strategic institutional investment provides financial flexibility to advance key growth initiatives and scale multiple business opportunities [4][8]. - The company aims to expand its market presence and execution capabilities through this new capital [8].

FORT MILL, S.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture retention device will be highlighted during live procedural cases at the Structural Heart Intervention and Imaging: A Practical Approach 2026 conference. The event, hosted by Scripps Health, will take place from February 11–13, 2026, at the Hyatt Regency La Jolla at Aventine in San Diego. The Scripp ...

Core Insights - Catheter Precision, Inc. has reported a surge in hospital evaluations and approvals for its LockeT suture retention device, indicating strong progress in product adoption both domestically and internationally as of Q1 2026 [1][2] Product Adoption - The company achieved its highest recorded revenue for January and has entered several international markets, securing evaluations at additional high-volume centers in the U.S. These evaluations are essential for long-term purchasing agreements [2] - Initial feedback from hospital partners suggests that LockeT effectively addresses the need for efficient and cost-effective wound closure, with expectations for evaluations to transition into permanent adoption [3] Product Details - LockeT is a Class 1 suture retention device registered with the FDA and has received CE Mark approval, designed to assist in wound closure after percutaneous venous punctures [4] Company Overview - Catheter Precision is a U.S.-based medical device company focused on innovative solutions for cardiac arrhythmias, emphasizing collaboration with physicians to advance electrophysiology procedures [5] Operational Efficiency - LockeT's design allows for rapid staff onboarding, with training completed in several days at major institutions, enhancing operational efficiency [9] - The device facilitates same-day discharge and reduces post-procedural bed rest, presenting a strong economic case for hospitals [9] International Expansion - The company is expanding into the European closure market, leveraging its CE Mark approval and the economic advantages of LockeT [9]

Company Overview - Catheter Precision, Inc. is a US-based medical device company focused on developing advanced products for the cardiac electrophysiology market [5] - The company aims to improve the treatment of cardiac arrhythmias through innovative technology and collaboration with physicians [5] Product Launch - Catheter Precision has received a purchase order for its LockeT suture retention device from Universitätsklinikum Frankfurt, marking its entry into the German market [1][2] - The LockeT device is designed to enhance workflow efficiency after venous catheter access while being cost-effective [2][4] Market Significance - Germany is highlighted as the largest healthcare market in Europe, with the Electrophysiology Devices Market valued at over $900 million in 2024 [3] - The partnership with a prestigious university hospital in Germany is seen as a pivotal moment for Catheter Precision, establishing a foothold in a market known for innovation and high medical standards [3] Strategic Implications - The implementation of LockeT at Universitätsklinikum Frankfurt will serve as a reference site for future expansions across Germany and Europe [3] - This purchase order validates the clinical value of Catheter Precision's technology and supports its expansion strategy in the region [3]

Core Insights - Catheter Precision, Inc. has expanded its global sales footprint to 15 countries following a purchase order from the University Clinical Center Ljubljana in Slovenia [1][3]. Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing advanced products for the cardiac electrophysiology market [6]. - The company aims to improve the treatment of cardiac arrhythmias through innovative technology and collaboration with physicians [6]. Product Information - VIVO (View Into Ventricular Onset) is a non-invasive 3D imaging system that helps identify the origin of ventricular arrhythmias pre-procedure, streamlining workflow and reducing procedure time. It has received marketing clearance from the U.S. FDA and the CE Mark [5]. - LockeT is a suture retention device designed to assist in wound closure after percutaneous venous punctures. It is a Class 1 device registered with the FDA and has also received CE Mark approval [4]. Market Position and Growth - The recent purchase order signifies the company's successful navigation of international regulatory landscapes and the establishment of strong distribution partnerships [3]. - The CEO of Catheter Precision expressed optimism about the company's growth trajectory and the effectiveness of its products in addressing real-world challenges in electrophysiology lab workflows [3].

Core Viewpoint - Catheter Precision, Inc. has secured its first purchase order and a multi-year commitment for its LockeT device at Mater Private Hospital, Ireland's largest electrophysiology center, marking a significant step in the company's global expansion strategy and commitment to enhancing cardiac care safety and efficiency [1][4]. Group 1: Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for cardiac arrhythmias, emphasizing collaboration with physicians to advance electrophysiology procedures [6]. - The LockeT device is a suture retention device designed to assist in wound closure after percutaneous venous punctures, classified as a Class 1 device registered with the FDA and has received CE Mark approval [5]. Group 2: Product Implementation - The implementation of LockeT at Mater Private Hospital involved a rapid onboarding process, with the chief nurse training 52 staff members in just two days, highlighting the device's intuitive design and operational efficiency [3]. - Mater Private Hospital performs over 1,000 electrophysiology procedures annually, making it a crucial institution for arrhythmia treatment and innovation in Europe [2]. Group 3: Strategic Importance - The partnership with Mater Private Dublin is viewed as a major achievement for Catheter Precision, validating the technology and strengthening its position in the global electrophysiology market [4]. - The acceptance of LockeT at this hospital underscores the company's focus on expanding its international market presence and promoting technologies that enhance clinical outcomes [4].